ArticleOncology letters2017
MicroRNA-134 targets KRAS to suppress breast cancer cell proliferation, migration and invasion.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06726070 (Investigation of Candidate miRNAs as Potential Biomarkers in the Early Diagnosis of Prostate Cancer and Benign Prostate Hyperplasia), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Investigation of Candidate miRNAs as Potential Biomarkers in the Early Diagnosis of Prostate Cancer and Benign Prostate Hyperplasia
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Prognostic role of 14q32.31 miRNA cluster in various carcinomas: a systematic review and meta-analysis.Clinical & experimental metastasis · 2020Pooled it
- Target therapeutic exploitation of engineered exosome-mediated delivery of ncRNAs in cancer.Cancer gene therapy · 2026Review
- Subtype-Independent Activation of NF-κB Signaling in Breast Cancer.International journal of molecular sciences · 2026Article
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies.Medical oncology (Northwood, London, England) · 2024Review
- Associations of plasma extracellular microRNAs with new-onset breast cancer in the Framingham heart study.American journal of cancer research · 2024Article
- Critical Review on the Different Roles of Exosomes in TNBC and Exosomal-Mediated Delivery of microRNA/siRNA/lncRNA and Drug Targeting Signalling Pathways in Triple-Negative Breast Cancer.Molecules (Basel, Switzerland) · 2023Review
- Ruyiping formula inhibits metastasis via the microRNA-134-SLUG axis in breast cancer.BMC complementary medicine and therapies · 2021Article
- Novel Small Molecules Capable of Blocking mtRAS-Signaling Pathway.Frontiers in oncology · 2021Article
- miRNome Profiling Reveals Shared Features in Breast Cancer Subtypes and Highlights miRNAs That Potentially Regulate MYB and EZH2 Expression.Frontiers in oncology · 2021Article
- MicroRNA-134 prevents the progression of esophageal squamous cell carcinoma via the PLXNA1-mediated MAPK signalling pathway.EBioMedicine · 2019Article
- miR-202 acts as a potential tumor suppressor in breast cancer.Oncology letters · 2018Article
- microRNA-134 inhibits melanoma growth and metastasis by negatively regulating collagen triple helix repeat containing-1 (CTHRC1).International journal of clinical and experimental pathology · 2018Article
- Circulating miRNA Expression Profiling in Breast Cancer Molecular Subtypes: Applying Machine Learning Analysis in Bioinformatics.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The expression patterns and functions of microRNA-134 (miR-134) have been previously studied in numerous types of cancer. To the best of our knowledge, this is the first study of miR-134 in human breast cancer. In the present study, the expression patterns, biological functions and underlying molecular mechanisms of miR-134 in human breast cancer were investigated. Reverse transcription-quantitative polymerase chain reaction evaluated the expression of miR-134 in human breast cancer tissues, matched normal adjacent tissues, breast cancer cell lines and a normal mammary epithelial cell line. Following transfection with miR-134, an MTT assay, cell migration assay, cell invasion assay, western blot analysis and a luciferase assay were performed on the MCF-7 and MDA-MB-231 human breast cancer cell lines. The findings revealed that miR-134 expression levels were significantly downregulated in breast cancer cells. Statistical analysis demonstrated that low expression of miR-134 was significantly associated with lymph node metastasis, TNM stage and reduced cell differentiation. It was observed that miR-134 inhibited the growth, migration and invasion of breast cancer cells. Additionally, the present study indicated that miR-134 may directly target the Kirsten rat sarcoma viral oncogene homolog in breast cancer tissues. These results suggest that miR-134 may be used as a potential therapeutic biomarker in breast cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.